CN107669762A - One kind auxiliary antilipemic healthy piece and preparation method thereof - Google Patents
One kind auxiliary antilipemic healthy piece and preparation method thereof Download PDFInfo
- Publication number
- CN107669762A CN107669762A CN201711136164.7A CN201711136164A CN107669762A CN 107669762 A CN107669762 A CN 107669762A CN 201711136164 A CN201711136164 A CN 201711136164A CN 107669762 A CN107669762 A CN 107669762A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginseng
- fructus cannabis
- cassia seed
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000002402 anti-lipaemic effect Effects 0.000 title claims description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 42
- 241000218236 Cannabis Species 0.000 claims abstract description 34
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 34
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 34
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 23
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 23
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 23
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 23
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 23
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 23
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 23
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 23
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 23
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 23
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 23
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 235000005412 red sage Nutrition 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000000314 lubricant Substances 0.000 claims abstract description 12
- 238000007908 dry granulation Methods 0.000 claims abstract description 11
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- 238000002386 leaching Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000000748 compression moulding Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000010924 continuous production Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 20
- 241001092040 Crataegus Species 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 108010023302 HDL Cholesterol Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- -1 cholesteryl ester Chemical class 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of health-care tablet for aiding in reducing blood lipid and preparation method thereof, the raw material composition of the health-care tablet is according to the mass fraction：10 20 parts of American Ginseng, 15 25 parts of the red sage root, 10 20 parts of pseudo-ginseng, 5 15 parts of hawthorn, 5 15 parts of cassia seed, 5 15 parts of spina date seed, 10 20 parts of fructus cannabis, 0.5 2 parts of lubricant；Its preparation method：Fructus cannabis, cassia seed frying；American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed；Dry granulation, last tabletting.The production Technology of the present invention is simple to operate, industrialization continuous production can be achieved, therefore production cost is low.The tablet of production is easy to carry, easy to use.
Description
Technical field
The invention belongs to health products studying technological domain, is related to a kind of tablet, more particularly to a kind of auxiliary antilipemic healthy
Piece and preparation method thereof.
Background technology
In the blood of people, contained lipid is referred to as blood fat, including cholesterol, cholesteryl ester, triglyceride, phosphatide in blood plasma
Not esterified aliphatic acid etc..When cholesterol, triglycerides etc. exceed normal value, then with referred to as hyperlipemia.
As the improvement of people's living standards, the illness rate of hyperlipemia had what is significantly risen to become in recent years in population of China
Gesture.Hyperlipemia is the Main Etiological Factors of atherosclerosis, and causes the diseases such as coronary heart disease, diabetes, cerebral thrombus
Hazards.At present, treat that the medicine of hyperlipemia is a lot, but different degrees of side effect all be present in Western medicine reducing blood lipid, and
And it is difficult to effect a radical cure.
The present invention is directed to the crowd of Hyperlipidemia, based on tcm health preserving theory, with reference to modern medical theory, from west
American ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis are raw material prescription, have the health-care efficacy of auxiliary reducing blood lipid.
There is American Ginseng in side reduces the functions such as blood coagulability, antiatherosclerosis, regulation insulin secretion, promotion fat metabolism.
The red sage root, pseudo-ginseng have promoting blood circulation, reduce blood viscosity, improve microcirculation, scavenging activated oxygen, reduce lipid peroxidation in side
The functions such as thing content.Hawthorn, spina date seed, cassia seed have the defaecation that helps digestion, blood stasis removing analgesic, clearing heat and detoxicating, reduction blood lipid level in side,
Suppress lipid in functions such as liver, renal depositions.Fructus cannabis contains phytosterol, has the work(for reducing blood cholesterol level
Energy.To sum up, American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis be respectively by different mechanism of action and approach,
Carry out intervening the purpose for reaching reducing blood lipid from multi-level, Mutiple Targets, collaboration plays the function of auxiliary reducing blood lipid.
The content of the invention
The invention aims to provide a kind of health-care tablet for aiding in reducing blood lipid and preparation method thereof.The technique is obtained to produce
Product have significant health-care efficacy, and industrial production cost is low, are easy to carry, and have the good prospect of marketing.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of health-care tablet for aiding in reducing blood lipid, it is characterised in that：The raw material of the health-care tablet is formed by mass fraction ratio：The West
Join 10-20 parts, red sage root 15-25 parts, pseudo-ginseng 10-20 parts, hawthorn 5-15 parts, cassia seed 5-15 parts,
Spina date seed 5-15 parts, fructus cannabis 10-20 parts, lubricant 0.5-2 parts.
The present invention further discloses the preparation method of auxiliary antilipemic healthy piece, it is characterised in that enters by the steps
OK：
（1）Fructus cannabis, cassia seed frying：By fructus cannabis, cassia seed, frying 10-30 minutes are standby at 180 DEG C -250 DEG C；
（2）American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed：
Fructus cannabis after American Ginseng, the red sage root, pseudo-ginseng, hawthorn, spina date seed and frying, cassia seed raw material are subjected to pulverization process, place
Raw material soaking after reason is heated to 85 DEG C 1 hour in the purified water of 8 times of quality, with multi-function extractor, reduced-pressure backflow extraction 2
Hour, 150 mesh filter to obtain a leaching liquor；The purified water of 6 times of quality is added into filter residue, is soaked under same extraction temperature
Carry 1 hour, obtain secondary leaching liquor；Leaching liquor merging twice is concentrated under reduced pressure, is concentrated into relative density 1.05-1.20；Again
It is spray-dried standby into mixed extract powder；
（3）Dry granulation：By step（2）The mixed extract powder of preparation uses dry granulation mechanism in 100,000 grades of cleaning shops
Into particle；
（4）Tabletting：By step in 100,000 grades of cleaning shops（3）The particle and lubricant of preparation（Magnesium stearate）It is sufficiently mixed,
It is molded using tabletting machine, produces the health-care tablet of auxiliary reducing blood lipid.
Primary study of the present invention integration of drinking and medicinal herbs based food material combination is mainly solved using the feasibility of auxiliary reducing blood lipid
The problem of on the market reducing blood lipid is using Western medicine to be main at present.
How is the raw materials such as high spot reviews of the present invention American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis
With the use of can have auxiliary reducing blood lipid the effect of problem.
The pharmacological action for the Chinese medicine that the present invention uses is as follows：
American Ginseng：It is cool in nature, sweet, slight bitter, boosting qi and nourishing yin, clearing heat and promoting fluid.The long American Ginseng that takes can reduce blood coagulability, suppress
Platelet aggregation, antiatherosclerosis simultaneously promote Growth of red blood cells, increase hemochrome.In addition American Ginseng can also reduce blood
Sugar, regulation insulin secretion, promote glycometabolism and fat metabolism, have certain booster action to treatment diabetes.
The red sage root：Bitter, it is slightly cold, there is promoting blood circulation, inducing meastruation to relieve menalgia, relieving restlessness that clears away heart-fire, the effect of cool blood to disappear carbuncle.
Pseudo-ginseng：Sweet, slight bitter, temperature.With dissipate stasis of blood hemostasis, the effect of detumescence ding-tong.
Hawthorn：Sour sweet, tepor.Acted on reducing blood lipid, blood pressure, cardiac stimulant, arrhythmia etc., while be also that invigorating the spleen is opened
Stomach, relieving dyspepsia, the good medicine of phlegm reduction of blood circulation promoting, the disease such as, hernia, blood stasis full to chest diaphragm spleen, amenorrhoea have the effect of fine.
Cassia seed：Bitter, sweet, salty, cold nature, enter liver, kidney, large intestine channel；Relax bowel, lipid-loweringing improving eyesight, treat constipation and
High fat of blood, hypertension.Clear liver and improve vision, sharp water defaecation, there is laxative action, reducing blood pressure and blood fat.
Spina date seed：Property is sweet, and taste is put down.With antitoxic heart-soothing and sedative；Nourishing the liver；The effect of arrest sweating.Tune can be played by being shared with other medicinal materials
And the effect of.
Fructus cannabis：It is sweet, it is mild-natured.With defaecation diuresis, beneficial spleen qi-restoratives, nourishing yin to moisten dryness, spirit keeping and blood activating and other effects.It can drop
Blood fat, norcholesterol, pre- preventing thrombosis.Prevention and treatment heart disease.
Possessed advantage is auxiliary antilipemic healthy piece disclosed by the invention compared with prior art：
（1）Raw materials for production American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, the fructus cannabis of the present invention, is national food
Product Drug Administration ratifies and accreditation has auxiliary lipid-lowering function.
（2）Played in composition of raw materials of the present invention regulation blood fat function factor for plant polyose class, flavonoids, tanshinone,
Saponin(e and alkaloid etc..1. its mechanism of action mainly improves the work of lipoprotein lipase and lecithin cholesterol acyltransferase
Property, so as to promote lipid catabolism, suppress its synthesis transhipment and the deposition on arterial wall；2. with cholesterol or its conversion product
Cholic acid is combined or integrated, and so as to suppress its absorption in the intestine, promotes degraded and excretion；3. promoting blood circulation, reduction blood are viscous
Degree, improve microcirculation；4. scavenging activated oxygen, reduce lipid peroxide contents etc..
（3）The production Technology of the present invention is simple to operate, industrialization continuous production can be achieved, therefore production cost is low.It is raw
The tablet of production is easy to carry, easy to use.
Embodiment
The present invention is described below by specific embodiment.Unless stated otherwise, technological means used in the present invention
It is method known in those skilled in the art.In addition, embodiment is interpreted as illustrative, it is not intended to limit the present invention
Scope, the spirit and scope of the invention are limited only by the claims that follow.To those skilled in the art, without departing substantially from this
The various changes carried out on the premise of invention spirit and scope to the material component in these embodiments and dosage or change
Belong to protection scope of the present invention.Herbal raw material used in the present invention and reagent are commercially available.
Embodiment 1
A kind of health-care tablet for aiding in reducing blood lipid：10 parts of American Ginseng, 25 parts of the red sage root, 20 parts of pseudo-ginseng, 15 parts of hawthorn, 5 parts of cassia seed, acid
5 parts of jujube kernel, 19.5 parts of fructus cannabis, 0.5 part of lubricant；
The preparation method comprises the following steps：
（1）Fructus cannabis, cassia seed frying：By fructus cannabis, cassia seed, frying 30 minutes is standby at 180 DEG C；
（2）American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed：
Fructus cannabis after American Ginseng, the red sage root, pseudo-ginseng, hawthorn, spina date seed and frying, cassia seed raw material are subjected to pulverization process, place
Raw material soaking after reason is heated to 85 DEG C 1 hour in the purified water of 8 times of quality, with multi-function extractor, reduced-pressure backflow extraction 2
Hour, 150 mesh filter to obtain a leaching liquor；The purified water of 6 times of quality is added into filter residue, is soaked under same extraction temperature
Carry 1 hour, obtain secondary leaching liquor；Leaching liquor merging twice is concentrated under reduced pressure, is concentrated into relative density 1.05；Again through spraying
It is standby to be dried to mixed extract powder；
（3）Dry granulation：By step（2）The mixed extract powder of preparation uses dry granulation mechanism in 100,000 grades of cleaning shops
Into particle；
（4）Tabletting：By step in 100,000 grades of cleaning shops（3）The particle of preparation is sufficiently mixed with magnesium stearate lubricant, is adopted
It is molded with tabletting machine, produces the health-care tablet of auxiliary reducing blood lipid.
Embodiment 2
A kind of health-care tablet for aiding in reducing blood lipid：15 parts of American Ginseng, 15 parts of the red sage root, 15 parts of pseudo-ginseng, 10 parts of hawthorn, 15 parts of cassia seed,
15 parts of spina date seed, 14 parts of fructus cannabis, 1 part of lubricant；
The preparation method comprises the following steps：
（1）Fructus cannabis, cassia seed frying：By fructus cannabis, cassia seed, frying 20 minutes is standby at 220 DEG C；
（2）American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed：
Fructus cannabis after American Ginseng, the red sage root, pseudo-ginseng, hawthorn, spina date seed and frying, cassia seed raw material are subjected to pulverization process, place
Raw material soaking after reason is heated to 85 DEG C 1 hour in the purified water of 8 times of quality, with multi-function extractor, reduced-pressure backflow extraction 2
Hour, 150 mesh filter to obtain a leaching liquor；The purified water of 6 times of quality is added into filter residue, is soaked under same extraction temperature
Carry 1 hour, obtain secondary leaching liquor；Leaching liquor merging twice is concentrated under reduced pressure, is concentrated into relative density 1.10；Again through spraying
It is standby to be dried to mixed extract powder；
（3）Dry granulation：By step（2）The mixed extract powder of preparation uses dry granulation mechanism in 100,000 grades of cleaning shops
Into particle；
（4）Tabletting：By step in 100,000 grades of cleaning shops（3）The particle of preparation is sufficiently mixed with magnesium stearate lubricant, is adopted
It is molded with tabletting machine, produces the health-care tablet of auxiliary reducing blood lipid.
Embodiment 3
A kind of health-care tablet for aiding in reducing blood lipid：10 parts of American Ginseng, 20 parts of the red sage root, 10 parts of pseudo-ginseng, 10 parts of hawthorn, 15 parts of cassia seed,
15 parts of spina date seed, 18 parts of fructus cannabis, 2 parts of lubricant；
The preparation method comprises the following steps：
（1）Fructus cannabis, cassia seed frying：By fructus cannabis, cassia seed, frying 10 minutes is standby at 250 DEG C；
（2）American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed：
Fructus cannabis after American Ginseng, the red sage root, pseudo-ginseng, hawthorn, spina date seed and frying, cassia seed raw material are subjected to pulverization process, place
Raw material soaking after reason is heated to 85 DEG C 1 hour in the purified water of 8 times of quality, with multi-function extractor, reduced-pressure backflow extraction 2
Hour, 150 mesh filter to obtain a leaching liquor；The purified water of 6 times of quality is added into filter residue, is soaked under same extraction temperature
Carry 1 hour, obtain secondary leaching liquor；Leaching liquor merging twice is concentrated under reduced pressure, is concentrated into relative density 1.20；Again through spraying
It is standby to be dried to mixed extract powder；
（3）Dry granulation：By step（2）The mixed extract powder of preparation uses dry granulation mechanism in 100,000 grades of cleaning shops
Into particle；
（4）Tabletting：By step in 100,000 grades of cleaning shops（3）The particle of preparation is sufficiently mixed with magnesium stearate lubricant, is adopted
It is molded with tabletting machine, produces the health-care tablet of auxiliary reducing blood lipid.
The Report on Animal of test example 1：
Sample：Tablet prepared by embodiment 2, every 0.5 gram.
Experimental animal：SPF level health male SD rats, 200 ± 20 grams of body weight；22-25 DEG C of animal room temperature, relative humidity
55-75%。
Dosage choice and animal subject give mode：Inventive samples set 0.25,0.5,3 metering groups of 1.5g/kgbw
（It is respectively equivalent to 5,10,30 times of human body recommended amounts, respectively low dose group, middle dose group, high dose group）, each group animal is equal
Gavage, blank control group and high fat control group gavage isometric(al) distilled water are carried out by 1ml/100g body weight gavages volume.
Experimental method：According to《Function of health food assessment process and the method for inspection》（Version in 2003）It is required that evaluate this hair
The effect of bright.Rat is fed with basal feed in cleaning grade zoopery room and observed 7 days, adjoins after fasting 16h from the intraocular of rat
Blood sampling determines every observation index normal value.It is horizontal according to TC, rat is divided into 5 groups, every group using stratified random smapling method
10, and suitably adjustment makes TG, HDL-C of each group rat and original body mass as balanced as possible.After starting experiment, except blank control
Group is outer, and remaining each group is fed with high lipid food, while basic, normal, high dosage group rat oral gavage gives test solution, blank
Control group and high fat control group gavage give pure water.Weigh in weekly 1 time.Experiment to the 31st day blood sampling measure serum TC, TG,
HDL-C contents, animal fasting 16h before blood sampling.Serum TC, the measure of TG, HDL-C content use enzymatic reagent-end-point method.
Data Processing in Experiment：Variance analysis statistical disposition is carried out using SPSS statistical softwares.
Result judgement：In three serum total cholesterol, triglyceride, HDL-C indexs, serum is total
Two index positives of cholesterol and triglycerides, it can determine that given the test agent auxiliary reducing blood lipid zoopery is positive.
Experimental result：
1. influence of the inventive samples to rat body weight
It the results are shown in Table 1
Influence of the sample of table 1 to rat body weight
* there are marked difference P ＜ 0.05, * * P ＜ 0.01 compared with high fat control group
From table 1, rat is given 30 days with the inventive samples gavage of basic, normal, high dosage, each group growth of animal, activity are just
Often, test group animal and high fat control group weight ratio are without difference（P ＞ 0.05）.
2. inventive samples are to Serum TC, TG, HDL-C influence
2.1 inventive samples are to rat blood serum T-CHOL（TC）Influence
It the results are shown in Table 2
The sample of table 2 is to rat blood serum T-CHOL（TC）Influence
Note：* there are marked difference P ＜ 0.05, * * P ＜ 0.01 compared with high fat control group
2.2 inventive samples are to rat blood serum triglyceride（TG）Influence
It the results are shown in Table 3
The sample of table 3 is to rat blood serum triglyceride（TG）Influence
Note：* there are marked difference P ＜ 0.05, * * P ＜ 0.01 compared with high fat control group
2.3 inventive samples are to rat blood serum HDL-C（HDL-C）Influence
It the results are shown in Table 4
The sample of table 4 is to rat blood serum HDL-C（HDL-C）Influence
Note：* there are marked difference P ＜ 0.05, * * P ＜ 0.01 compared with high fat control group
From table 2,3,4, with 0.25,0.5, after the inventive samples gavage of 1.5g/kg dosage gives rat 30 days, it is high
The serum TC and TG of fat control group are higher than blank control group all the time and statistically significant, and it is successful to illustrate hyperlipidemia model.
The TC of middle and high dosage group serum has obvious reduction with high fat control group ratio（P respectively<0.05 and P ＜ 0.01）；Middle and high dosage group
Serum TG and the high obvious reduction of fat control group（P respectively<0.05 and P ＜ 0.01）.The serum of each group rat before and after experiment
HDL-C contents are basically identical, the no significant difference between each group.
3. result judgement
Respectively with 0.25,0.5, this hair of 1.5g/kgbw (being respectively equivalent to 5,10,30 times that human body recommends dosage) dosage
The rat continuous gavage that is fed with to high lipid food of bright sample 30 days, the serum total cholesterol (TC) and glycerine three of rat can be reduced
Ester (TG) content, serum High Density Lipoprotein Cholesterol (HDL-C) content of rat is influenceed without obvious, prompts the present invention
Sample there is auxiliary lipid-lowering function.There is the significant difference on statistical significance, card compared with normal control group simultaneously
After bright material combination of the invention, synergy is generated, there is unexpected technique effect.
The test-meal of experimental example 2 is tested：
1. Liu XX, man, 60 years old, Hyperlipidemia, with diabetes, after drinking half a year of the invention, blood fat recovered normal.
2. Korea Spro XX, man, 54, Hyperlipidemia, it is particularly easy to feel fatigue, often feels dizzy, take the present invention 1 month
Afterwards, above-mentioned symptom substantially improves, and it is normal to continue above-mentioned symptom disappearance blood fat substantially after taking half a year of the invention.
The foregoing is only presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, it should all belong to the covering scope of the present invention.
Claims (5)
- A kind of 1. health-care tablet for aiding in reducing blood lipid, it is characterised in that：The raw material of the health-care tablet is formed by mass fraction ratio：West American ginseng 10-20 parts, red sage root 15-25 parts, pseudo-ginseng 10-20 parts, hawthorn 5-15 parts, cassia seed 5-15 parts,Spina date seed 5-15 parts, fructus cannabis 10-20 parts, lubricant 0.5-2 parts.
- 2. the preparation method of the auxiliary antilipemic healthy piece described in claim 1, it is characterised in that carried out by the steps：（1）Fructus cannabis, cassia seed frying：By fructus cannabis, cassia seed, frying 10-30 minutes are standby at 180 DEG C -250 DEG C；（2）American Ginseng, the red sage root, pseudo-ginseng, hawthorn, cassia seed, spina date seed, fructus cannabis raw material extract powder processed：Fructus cannabis after American Ginseng, the red sage root, pseudo-ginseng, hawthorn, spina date seed and frying, cassia seed raw material are subjected to pulverization process, place Raw material soaking after reason is heated to 85 DEG C 1 hour in the purified water of 8 times of quality, with multi-function extractor, reduced-pressure backflow extraction 2 Hour, 150 mesh filter to obtain a leaching liquor；The purified water of 6 times of quality is added into filter residue, is soaked under same extraction temperature Carry 1 hour, obtain secondary leaching liquor；Leaching liquor merging twice is concentrated under reduced pressure, is concentrated into relative density 1.05-1.20；Again It is spray-dried standby into mixed extract powder；（3）Dry granulation：By step（2）The mixed extract powder of preparation uses dry granulation mechanism in 100,000 grades of cleaning shops Into particle；（4）Tabletting：By step in 100,000 grades of cleaning shops（3）The particle of preparation is sufficiently mixed with lubricant, using tablet press machine Compression molding, produce the health-care tablet of auxiliary reducing blood lipid.
- 3. the health-care tablet of the auxiliary reducing blood lipid described in claim 1, it is characterised in that the lubricant is magnesium stearate.
- 4. aid in application of the antilipemic healthy piece in auxiliary treatment Secondary cases hyperlipemia medicine is prepared.
- 5. the application described in claim 4, Secondary cases hyperlipemia therein refers to：Three high crowds and obese people.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711136164.7A CN107669762A (en) | 2017-11-16 | 2017-11-16 | One kind auxiliary antilipemic healthy piece and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711136164.7A CN107669762A (en) | 2017-11-16 | 2017-11-16 | One kind auxiliary antilipemic healthy piece and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107669762A true CN107669762A (en) | 2018-02-09 |
Family
ID=61149605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711136164.7A Pending CN107669762A (en) | 2017-11-16 | 2017-11-16 | One kind auxiliary antilipemic healthy piece and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669762A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108497494A (en) * | 2018-04-16 | 2018-09-07 | 西安金穗生物科技有限责任公司 | A kind of health food and preparation method thereof of auxiliary reducing blood lipid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721507A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for relieving and treating fatty livers and preparation method thereof |
-
2017
- 2017-11-16 CN CN201711136164.7A patent/CN107669762A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721507A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for relieving and treating fatty livers and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 庄瑞丰: "中药降血脂作用研究进展", 《河北医药》 * |
| 黄纯琪: "三高散", 《中国民间疗法》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108497494A (en) * | 2018-04-16 | 2018-09-07 | 西安金穗生物科技有限责任公司 | A kind of health food and preparation method thereof of auxiliary reducing blood lipid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107296949A (en) | Integration of drinking and medicinal herbs compound formulation and its preparation method and application | |
| CN106606529A (en) | Composition with auxiliary blood sugar reduction efficacy, and preparation method and application thereof | |
| CN102604797B (en) | Beautifying and detoxifying wine and its preparation method | |
| CN104757540A (en) | Health-care product assisted to reduce blood glucose and preparation method thereof | |
| CN105456622A (en) | Traditional Chinese medicine composition and preparation for treating impaired glucose regulation and preparation method thereof | |
| CN108522994A (en) | Radix Astragali oat rice flour | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN103155985B (en) | Rhizoma polygonati nutrition powder and preparation method thereof | |
| CN106138941A (en) | A kind of improve sleep and the compound Chinese medicinal preparation of auxiliary improvement of memory and preparation method | |
| CN102715322A (en) | Food skin nourishing tea granule | |
| CN107412439A (en) | The ginseng composition and preparation method of auxiliary adjustment menopause symptom and anti-cancer and cancer-preventing | |
| CN107773679A (en) | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus | |
| CN107669762A (en) | One kind auxiliary antilipemic healthy piece and preparation method thereof | |
| CN103690819A (en) | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function | |
| CN108935818A (en) | A kind of Qingqian Willow leaf health drink tea and preparation method thereof | |
| CN108420890A (en) | A kind of composition and preparation method thereof with effect for reducing blood fat | |
| CN106361976A (en) | Compound preparation for calming nerves, promoting sleep and keeping beauty and preparation method of compound preparation | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN105055570B (en) | A kind of Chinese medicinal composition for reducing blood fat and its preparation and preparation process | |
| CN105168160B (en) | A kind of tablet of antelope's horn for common cold and preparation method thereof | |
| CN103285110B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof | |
| CN102715508B (en) | Compound walnut soft shell capsule enhanced nourishment | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function | |
| CN109288058A (en) | A kind of active health-care preparation of fullerene enhancing normal cell and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No.26, Baidi Road, Nankai District, Tianjin 300192 Applicant after: Tianjin Academy of Agricultural Sciences Address before: 300384 17 kilometers, Jin Jing Road, Xiqing District, Tianjin Applicant before: TIANJIN AGRICULTURAL BIO-TECH RESEARCH CENTER |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180209 |